Recent advances in the development of agonists selective for beta1-type thyroid hormone receptor.
This mini-review will provide an overview on the recent design principles and structure-activity-relationship of beta-selective thyroid hormone receptor (TR) agonists. The prospects for the treatment of metabolic diseases as dyslipidemia with TRbeta-selective ligands are considerable enough so as to avoid cardiovascular acceleration mediated through TRalpha.